2023
Pediatric renal malignancy diagnosis is associated with significant burden of care for families
Leraas H, Thompson S, Sandoe E, Robles J, Wagner L, Scales C, Gow K, Ehrlich P, Greenup R, Tracy E. Pediatric renal malignancy diagnosis is associated with significant burden of care for families. Pediatric Blood & Cancer 2023, 70: e30494. PMID: 37337248, DOI: 10.1002/pbc.30494.Peer-Reviewed Original ResearchHealthcare utilizationRenal malignancySolid tumor diagnosisNorth Carolina MedicaidComplex care coordinationBurden of careChildhood cancer diagnosisRenal tumor diagnosisTumor diagnosisSubsequent nephrectomyMedian ageStudy criteriaCare coordinationRenal tumorsCancer regimensPatient visitsDiseases codesMalignancy diagnosisInternational ClassificationSignificant burdenMedical careDiagnosisCancer diagnosisMonthsMedical facilitiesReal world utilization and outcomes of immunotherapy regimens in metastatic castration resistant prostate cancer (mCRPC).
Ganta T, Anker J, Miller E, Tsao K, Oh W. Real world utilization and outcomes of immunotherapy regimens in metastatic castration resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2023, 41: e17038-e17038. DOI: 10.1200/jco.2023.41.16_suppl.e17038.Peer-Reviewed Original ResearchMetastatic castration resistant prostate cancerImmune checkpoint inhibitorsOverall survivalResponse rateCastration resistant prostate cancerSingle-center retrospective studyPSA response rateMedian overall survivalResistant prostate cancerOvercome treatment resistanceNon-metastatic diseaseKaplan-Meier curvesOff-label prescribingCheckpoint inhibitorsCancer regimensImmunotherapy regimensMedian durationProstate cancerCombinatorial regimensTreatment resistanceRetrospective studyTreatment paradigmChart reviewHistorical cohortTreatment options
2016
Cost Differential of Chemotherapy for Solid Tumors.
Nadeem H, Jayakrishnan T, Rajeev R, Johnston F, Gamblin T, Turaga K, Nadeem H, Jayakrishnan T, Rajeev R, Johnston F, Gamblin T, Turaga K. Cost Differential of Chemotherapy for Solid Tumors. JCO Oncology Practice 2016, 12: e299-307, 251. PMID: 26860586, DOI: 10.1200/jop.2015.006700.Peer-Reviewed Original ResearchConceptsSolid tumorsCurative therapyNational Comprehensive Cancer Network guidelinesNational Comprehensive Cancer NetworkBreast cancer regimensCancer therapy regimensComprehensive Cancer NetworkCost of chemotherapyUS adult malesMetastatic cancer therapyCancer regimensChemotherapy regimensChemotherapeutic regimensTherapy regimensNetwork guidelinesBaseline drugRegimensChemotherapyTreatment periodCancer therapyCancer NetworkMedian costPractice patternsTumorTherapy
2015
Chemotherapy-related amenorrhea after adjuvant paclitaxel–trastuzumab (APT trial)
Ruddy KJ, Guo H, Barry W, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Hudis C, Krop IE, Burstein HJ, Winer EP, Partridge AH, Tolaney SM. Chemotherapy-related amenorrhea after adjuvant paclitaxel–trastuzumab (APT trial). Breast Cancer Research And Treatment 2015, 151: 589-596. PMID: 25981899, PMCID: PMC5057177, DOI: 10.1007/s10549-015-3426-z.Peer-Reviewed Original ResearchConceptsChemotherapy-related amenorrheaChemotherapy initiationMenopausal symptomsBreast cancerAdjuvant breast cancer therapyEarly-stage breast cancerNode-negative HER2Weeks of paclitaxelStage breast cancerLast menstrual periodBreast cancer therapyAdjuvant paclitaxelAmenorrhea ratesAPT trialEligible patientsEvaluable populationPremenopausal womenAdjuvant studiesTrastuzumab monotherapyMedian timeMenstrual periodCancer regimensAmenorrheaTrastuzumabMonths
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply